EXOZ: R&D expansion and NCT progress meet a near-term funding shortfall and going-concern risk
Czytanie zajmuje mniej niż 1 minutę
Q3 net loss narrowed slightly YoY, but nine-month losses and operating cash use increased as R&D investment expanded. June offerings funded operations, yet management cited substantial doubt about runway; NCT scale-up and 2027 regulatory and human-study milestones remain key.
Original document: eXoZymes Inc. [EXOZ] SEC 10-Q Quarterly Report — Nov. 19 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr